Atomo Diagnostics Limited announced the signing of an agreement with Hangzhou AllTest Biotech Co., Ltd, (AllTest) for supply of a COVID-19 1 Rapid Antigen self-test in the Australian and New Zealand markets under the Atomo brand and provide a TGA Update. Atomo to seek to register in Australia and New Zealand as product sponsor, an Atomo branded version of AllTest's existing TGA approved COVID-19 Rapid Antigen self-test; Australian Register of Therapeutic Goods (ARTG No): 374574. Atomo has ordered an initial quantity of current JusChek branded product due in Australia late August to enable commercial launch to commence in parallel with activities to register an Atomo branded version of the product, with registration anticipated during Q.2 FY23.

Atomo and AllTest to continue discussions related to an expanded relationship with focus on commercialisation of blood based rapid tests in the US market, utilising Atomo's integrated test platform, the Atomo APP and AllTest's extensive range of commercialised rapid test assays currently being sold by AllTest in non-US markets. The company now intends to withdraw its existing submission to TGA related to the Atomo branded version of the Access Bio COVID-19 Rapid Antigen self-test and focus its commercial efforts on the AllTest product, which is categorised as "High sensitivity" by the TGA and is available at a competitive price point.